6 Best Peptides for Vaginal Dryness

What to Know Before Choosing a Peptide for Vaginal Dryness

Vaginal dryness sits at an interesting crossroads in the peptide world. It is a condition with well-established conventional treatments, and it is also one where a meaningful number of women, particularly those who cannot use estrogen-based therapies, are actively exploring alternatives. Peptides are part of that conversation, and this guide maps the ones people are actually using and discussing.

A compound earned its place here for one reason: people use it or are actively discussing using it for vaginal dryness. That is the only test. FDA-approved compounds qualify, telemedicine-prescribed compounds qualify, and research-only compounds qualify. Evidence strength is stated honestly inside each entry rather than used as a filter. The result is a list that includes oxytocin, which has published pilot trial data, and also Zhenoluten, whose English-language clinical record is thin but whose use in Eastern European bioregulator practice is real and ongoing. Both belong because both are part of the actual conversation.

The numbers in front of each entry give the list a spine and reflect how prominently each compound appears in research and real-world use for this goal, from the most to the least established. They are not a recommendation that compound one is better than compound six for you. Individual responses to peptides vary considerably, the right compound depends on your history, your hormonal status, and your other health considerations, and the personalized decision is something the app is built to help you work through.

One important context-setter: no peptide is currently FDA-approved specifically for vaginal dryness. Standard first-line care remains vaginal estrogen, non-hormonal prescription options like ospemifene and vaginal DHEA (prasterone), and over-the-counter options like hyaluronic acid suppositories. Peptides are being explored as complementary or alternative approaches, primarily in integrative and regenerative medicine settings, and the evidence base for most of them is earlier-stage than for those established options.

1. Oxytocin: The Only Peptide with Human Trial Data for Vaginal Atrophy

Oxytocin is a neuropeptide hormone produced naturally in the hypothalamus, best known for its roles in labor, breastfeeding, and social bonding. What most people do not know is that it has been studied as a topical vaginal gel specifically for vaginal atrophy in postmenopausal women, and it is the only compound in this list with published randomized pilot trial data for this exact use.

The mechanism here is direct rather than hormonal. Oxytocin appears to act on the vaginal epithelium, the layer of cells lining the vaginal walls, to improve its maturation and health. It improves the vaginal maturation index, a clinical measure that tracks the proportion of healthy, mature epithelial cells, and it brings vaginal pH closer to premenopausal levels. Because it does not work through estrogen receptors, it is particularly relevant for women who cannot use estrogen-based therapies, including breast cancer survivors.

The clinical evidence is early but real. A double-blind pilot study found that topical oxytocin gel improved vaginal epithelial health and reduced atrophy symptoms in postmenopausal women. A subsequent analysis found improvements in epithelial integrity and pH that outperformed placebo by a substantial margin across both measures. These are pilot-scale findings rather than large confirmatory trials, so the picture is promising rather than definitive. Still, it is peer-reviewed human data, which puts oxytocin in a different category from most of the other compounds people are discussing for this goal.

In practice, oxytocin for vaginal atrophy is available as a compounded vaginal gel through licensed compounding pharmacies, typically requiring a prescription from a physician who works with compounding. It is not FDA-approved for this specific indication. Oxytocin as a molecule has FDA approval for obstetric use in labor, but the compounded vaginal gel formulation for atrophy is an off-label application. Women using it under physician supervision apply it as a vaginal gel on a defined daily schedule for a course of weeks, mirroring the protocol structure the published studies evaluated.

For women in the peptide conversation around vaginal dryness, oxytocin is the strongest starting point from an evidence standpoint, and its non-hormonal mechanism makes it a genuinely distinct option from conventional estrogen-based care.

2. BPC-157: The Tissue-Repair Peptide Used in Regenerative Protocols

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide, meaning a chain of fifteen amino acids, derived from a protein found in human gastric juice. It is one of the most widely discussed peptides in regenerative medicine, appearing in protocols for tendon repair, gut healing, and tissue recovery across a broad range of conditions. Vaginal dryness is among the more recent applications gaining traction in integrative wellness settings.

The reason BPC-157 appears in protocols for vaginal dryness is mechanistic. It promotes angiogenesis, the growth of new blood vessels, by upregulating VEGF, which stands for vascular endothelial growth factor and is essentially the chemical signal that tells the body to build new capillary networks. Vaginal atrophy involves reduced blood flow to the tissue, and restoring capillary density is one of the key ways to reverse the thinning and dryness that follow. BPC-157 also promotes the synthesis of Type I and Type III collagen, the structural proteins that give vaginal walls their thickness and elasticity. The combined effect is a two-pronged approach: improve vascular supply and rebuild the structural matrix.

The evidence for this specific use is not from peer-reviewed clinical trials. No published randomized controlled trial has evaluated BPC-157 for vaginal dryness or vaginal atrophy in humans as of 2026. What exists is preclinical and mechanistic data supporting BPC-157's effects on angiogenesis and collagen synthesis broadly, along with practitioner-reported protocols from integrative and regenerative medicine clinics that describe improvements in tissue quality and dryness symptoms. The figures that circulate in wellness literature about improvement rates come from those practitioner sources rather than controlled studies, and that distinction matters when evaluating the evidence.

BPC-157 is classified as a research chemical in the United States, without FDA approval for any specific indication. It is typically obtained through compounding pharmacies when used in a clinical setting or through research chemical suppliers, and the quality of the latter varies considerably. Anyone considering it in a clinical context needs to source it through a licensed compounding pharmacy under physician supervision. It is administered by subcutaneous injection in most protocols, and it appears in both standalone protocols and in combination with TB-500.

3. TB-500: The Cellular-Repair Partner in Combination Protocols

TB-500 is a synthetic analog of Thymosin Beta-4, a small protein present in virtually every human and animal cell that plays a central role in cellular repair and regeneration. It is rarely used alone for vaginal dryness. The community protocols that feature it almost always pair it with BPC-157, and understanding why requires seeing what each one contributes.

Where BPC-157 works primarily on the vascular side, stimulating new blood vessel growth and collagen production, TB-500 works on the cellular side. It regulates actin, the structural protein that makes up much of the cell's internal scaffolding, and actin regulation is central to how cells migrate toward sites of damage and proliferate to rebuild injured tissue. TB-500 also reduces inflammatory cytokines, the chemical signals that sustain chronic inflammation in damaged tissue, which creates a calmer environment for repair to proceed. In the context of vaginal atrophy, the combination addresses both the blood supply problem and the epithelial barrier problem simultaneously, which is the rationale practitioners cite for pairing the two compounds.

Like BPC-157, TB-500 has no published human clinical trial data for vaginal dryness as of 2026. The evidence base is mechanistic, supported by preclinical data on its cellular repair properties, and protocol-based, drawn from the same regenerative medicine clinic reports that describe the BPC-157 combination. Community-reported experiences almost always describe the combination rather than either compound alone, so separating the contribution of each is not possible from current data.

TB-500 carries an additional regulatory note: it is listed as a prohibited substance by the World Anti-Doping Agency in sports contexts. It is not FDA-approved for any indication, and like BPC-157, its use in a clinical setting requires physician supervision and sourcing through a licensed compounding pharmacy. The evidence here is experiential and preclinical, and the compound belongs in this list because it is a standard part of the regenerative protocol conversation for vaginal tissue repair, not because a controlled trial has confirmed its effectiveness for this specific use.

4. PT-141: The FDA-Adjacent Peptide Used Off-Label for Blood Flow

PT-141, also known by its generic name bremelanotide and its brand name Vyleesi, occupies an unusual place in this list. It is the only peptide here with FDA approval for any aspect of female sexual function, though the approved indication is hypoactive sexual desire disorder in premenopausal women, not vaginal dryness. Its mechanism is also distinct from every other entry: it works through the central nervous system rather than directly on vaginal tissue.

PT-141 is a melanocortin agonist. It activates MC4 receptors in the brain, which are part of the pathway linking arousal signals in the central nervous system to physical response in the body. One of those physical responses is peripheral vasodilation, meaning blood vessels in the genital area relax and blood flow increases. That increase in genital blood flow is the mechanism through which PT-141 is used off-label for vaginal dryness, particularly in women where low arousal is contributing to reduced lubrication.

The key distinction is that PT-141 does not directly address the tissue atrophy, collagen loss, or epithelial thinning that characterize genitourinary syndrome of menopause. Its pathway is arousal and blood flow, not structural tissue repair. Some telehealth clinics offer compounded bremelanotide to menopausal women for this off-label application, and user-reported experiences describe improvements in arousal-related lubrication. The human trial data for vaginal dryness specifically is limited, and the FDA approval does not extend to this use or to postmenopausal women.

The regulatory picture for compounded forms is worth noting: compounded bremelanotide as a nasal spray or troche is not FDA-approved even in the hypoactive sexual desire disorder context, where only the injected form carries approval. For women whose dryness is primarily or partly driven by low arousal and reduced blood flow rather than structural atrophy, PT-141's mechanism is relevant, but it should be understood as an arousal pathway intervention rather than a tissue-rebuilding one.

5. Bioactive Collagen Peptides: The Oral Option Under Active Clinical Investigation

Bioactive collagen peptides are short-chain fragments of collagen taken orally as a supplement. They are technically nutraceuticals rather than injectable peptide therapies, but they belong in this list because they are being actively evaluated in registered clinical trials specifically for genitourinary syndrome of menopause, the umbrella condition that includes vaginal dryness, and they represent the most clinically advanced approach in the non-hormonal oral supplement category.

The mechanism relies on what researchers call bioactive messengers. When short collagen peptide fragments are absorbed from the gut, they circulate in the bloodstream and interact with fibroblasts, the cells responsible for producing structural proteins throughout the body. Those fibroblasts respond by increasing their synthesis of collagen and elastin, supporting tissue hydration and elasticity including in the vaginal walls. The specific effect on vaginal dryness is under investigation rather than established, but the biological rationale is grounded in how collagen peptide supplementation affects connective tissue broadly.

The clinical evidence is early and actively developing. An ongoing registered trial is evaluating oral bioactive collagen peptides in menopausal women with genitourinary syndrome symptoms including vaginal atrophy and urinary incontinence over sixteen weeks, with quality of life and sexual function as outcome measures. A second ongoing trial is testing oral collagen peptides in women with genital lichen sclerosus undergoing fat grafting. A published pilot study found that combining oral collagen peptides with vulvovaginal radiofrequency therapy improved genitourinary syndrome symptoms and vaginal pH, though benefits diminished over time without ongoing supplementation. These are pilot-scale and still-enrolling findings rather than completed large trials, so the evidence is promising and active rather than definitive.

For women who prefer a hormone-free oral option that is under active clinical investigation, bioactive collagen peptides are the most clinically grounded entry point in that category. The practical form is an oral supplement taken daily, and the trials evaluating it are using multi-month treatment courses.

6. Zhenoluten: The Ovarian Bioregulator from Eastern European Practice

Zhenoluten is a peptide bioregulator, a class of very short peptides, typically two to four amino acids in length, designed to exert organ-specific effects by penetrating cell nuclei and influencing gene expression in the target tissue. The class was developed primarily in Russia, most prominently at the St. Petersburg Institute of Bioregulation and Gerontology, and its use remains most established in Eastern European clinical practice.

Zhenoluten is specifically formulated to target ovarian and reproductive tissue. The theoretical basis for its relevance to vaginal dryness is that ovarian function decline is a primary driver of the hormonal changes that produce vaginal atrophy, and that a bioregulator targeting that tissue might support the restoration of more normal signaling over time. Practitioners who use peptide bioregulators describe them as working gradually, with effects accumulating over months rather than appearing rapidly, in contrast to the more acute vascular mechanisms of BPC-157 or the CNS-pathway activation of PT-141.

The honest picture on evidence: no English-language clinical trial data specifically evaluating Zhenoluten for vaginal dryness appears in the published literature reviewed for this article as of 2026. The broader peptide bioregulator category has a body of Russian-language research, and there is general work on bioregulators and aging-related tissue changes, but condition-specific, peer-reviewed English-language data for Zhenoluten and vaginal symptoms is not available. What exists is use within Eastern European integrative practice and growing interest from the global bioregulator community. This compound is included because it is genuinely discussed and used in the context of female reproductive tissue support, not because its evidence base matches the other entries.

Zhenoluten is primarily available through suppliers and practitioners who specialize in peptide bioregulators, and it is not FDA-approved. It is taken orally in the bioregulator convention, typically in short courses repeated periodically rather than by continuous daily injection-based protocols. For anyone considering it, the evidence here is practice-based and category-supported rather than condition-specific, and that context should be part of any conversation with a knowledgeable prescriber.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for vaginal dryness?

No peptide is currently FDA-approved specifically for vaginal dryness. PT-141 (Vyleesi) has FDA approval for hypoactive sexual desire disorder in premenopausal women, which is an adjacent but distinct indication, and compounded oxytocin vaginal gel is used off-label under physician supervision. The FDA-approved options for vaginal dryness itself are non-peptide treatments including vaginal estrogen, ospemifene, and vaginal DHEA (prasterone).

Which of these has the strongest human evidence?

Oxytocin has the strongest published human evidence among the peptides discussed here for this specific goal. A double-blind pilot study found measurable improvements in vaginal epithelial health and pH in postmenopausal women using topical oxytocin gel. Bioactive collagen peptides are the only other compounds with active registered clinical trials for genitourinary syndrome of menopause. BPC-157, TB-500, and Zhenoluten have no completed human trials for vaginal dryness available in the English-language literature as of 2026.

Can peptides replace vaginal estrogen for dryness?

Based on current evidence, no peptide has demonstrated equivalence to vaginal estrogen for vaginal dryness. Vaginal estrogen remains the most consistently effective treatment across both clinical trials and large-scale patient experience. Peptides are being explored as complementary approaches or as alternatives for women who cannot use estrogen-based therapies, such as some breast cancer survivors, but the evidence supporting them as standalone replacements is not yet established.

Is it safe to use peptides for vaginal dryness without medical supervision?

Using peptides from unregulated sources without medical supervision carries real risks, including contaminated or mislabeled products, unknown interactions, and the absence of any safety monitoring. Unapproved peptide products have been linked to serious adverse events in published health authority reports. Anyone considering peptides for this use should work with a physician and source compounds only through licensed compounding pharmacies rather than gray-market suppliers.

Why do so many of these peptides have thin evidence for this use?

Vaginal dryness as a peptide research target is genuinely early-stage. Most peptide research has focused on wound healing, metabolic conditions, and musculoskeletal repair, where the mechanism overlap with compounds like BPC-157 is more direct. The specific application to vaginal tissue is newer, and the clinical trial infrastructure to study it is just beginning to develop, as seen with the ongoing bioactive collagen peptide trials. Thin evidence is a description of where the field currently stands, not a judgment that the compounds are ineffective, and it means the honest answer for most of these is that controlled human research has not yet caught up to what practitioners and users are already trying.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and user-reported real-world use of peptides for vaginal dryness in one place.